IVIG - BMC HealthNet Plan

101. O’Donnell BF, Barr RM, Kobza A, et al. Intravenous immunoglobulin in
autoimmune chronic urticaria. Br J Dermatol. 1998;138:101-106.
102. Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin
in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol.
2007;39:237-242.
103. Asero R. Are IVIG for chronic unremitting urticaria effective Allergy.
2000;55:1099-1101.
104. Dawn G, Urcelay M, Ah-Weng A, et al. Effect of high-dose intravenous
immunoglobulin in delayed pressure urticaria. Br J Dermatol. 2003;149:836-840.
105. Joint Task Force on Practice Parameters. The diagnosis and management of
urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic
urticaria/angioedema: Joint Task Force on Practice Parameters. Ann Allergy Asthma
Immunol. 2000;85(6 Pt 2):521-544.
106. Powell RJ, Du Toit GL, Siddique N, et al; British Society for Allergy and Clinical
Immunology (BSACI). BSACI guidelines for the management of urticaria in adults
and children. Br J Dermatol. 2007;157:1116-1123.
107. Becker MD, Rosenbaum JT. Current and future trends in the use of
immunosuppressive agents in patiens with uveitis. Curr Opin Ophthalmol.
2000;11:472-477.
108. Onal S. Efficacy of intravenous immunoglobulin treatment in refractory uveitis.
Ocul Immunol Inflamm. 2006;14:367-374.
109. LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for
the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2000;8:49-57.
110. Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for
postexposure prophylaxis of varicella available under an investigational new drug
application expanded access protocol. MMWR Morb Mortal Wkly Rep. 2006;55:209-
210.
111. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCAassociated
systemic vasculitis with persistent disease activity. QJM. 2000;93:433-
439.
112. Martinez V, Cohen P, Pagnoux C, et al; French Vasculitis Study Group.
Intravenous immunoglobulins for relapses of systemic vasculitides associated with
antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, openlabel
study of twenty-two patients. Arthritis Rheum. 2008;58:308-317.
113. Relkin N, Szabo, Adamiak B, et al. Intravenous immunoglobulin (IVIG)
treatment causes dose-dependent alterations in β-amyloid (Aβ) levels and anti- Aβ
antibody titers in plasma and cerebrospinal fluid (CSF) of Alzheimer’s disease (AD)
patients [abstract]. Presented at: American Academy of Neurology 57th Annual
Meeting; April 12, 2005: Miami Beach, FL.
114. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing
antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol
Neurosurg Psychiatry. 2004;75:1472-1474.
This guideline provides information on BMC HealthNet Plan claims adjudication processing guidelines. The use of this
guideline is not a guarantee of payment and will not determine how a specific claim(s) will be paid. Reimbursement is
based on member benefits and eligibility, medical necessity review, where applicable, coordination of benefits, adherence
to Plan policies, clinical coding criteria, and the BMC HealthNet Plan agreement with the rendering or dispensing provider.
Reimbursement policies may be amended at BMC HealthNet Plan’s discretion. BMC HealthNet Plan will always use the
most recent CPT and HCPCS coding guidelines.
BMC HealthNet Plan – IVIG
40 of 45